{"name":"TJ Biopharma Co., Ltd.","slug":"tj-biopharma-co-ltd","ticker":"","exchange":"","domain":"tj-biopharma-co-ltd.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"TJ202, Lenalidomide and Dexamethasone","genericName":"TJ202, Lenalidomide and Dexamethasone","slug":"tj202-lenalidomide-and-dexamethasone","indication":"Multiple myeloma","status":"phase_3"},{"name":"NordiFlex","genericName":"NordiFlex","slug":"nordiflex","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TJ101","genericName":"TJ101","slug":"tj101","indication":"Phase 3 for [insert indication here, if known]","status":"phase_3"}]}],"pipeline":[{"name":"TJ101","genericName":"TJ101","slug":"tj101","phase":"phase_3","mechanism":"TJ101 is a small molecule that targets the [insert target here, if known].","indications":["Phase 3 for [insert indication here, if known]"],"catalyst":""},{"name":"TJ202, Lenalidomide and Dexamethasone","genericName":"TJ202, Lenalidomide and Dexamethasone","slug":"tj202-lenalidomide-and-dexamethasone","phase":"phase_3","mechanism":"Lenalidomide is an immunomodulatory drug that stimulates the immune system to attack cancer cells, while dexamethasone is a corticosteroid that has anti-inflammatory and immunosuppressive properties.","indications":["Multiple myeloma","Mantle cell lymphoma"],"catalyst":""},{"name":"NordiFlex","genericName":"NordiFlex","slug":"nordiflex","phase":"phase_3","mechanism":"NordiFlex is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNUFE1TWVKZ0VoNm9tVG10Rk50SzZuTnJKTmNPajZScVg1ZHVaS0ZYQ09ncEoxSGFSQ2hMOFZrZEhpZWhMd3hpZVRXSjlpODVGVmRJUGN0aXBBaEtfMnR0ZVBFLWVyV3FlZ0JTTFc3dmVCMHNJQUxxaWR1LUhsR2tLa2R3T3Q2UkFkQXJaOVlzRkxwOEptTFM2Zi1seXpBa2Q0Q2FDS29NSDh5aWJhWllKR19Ib0pTYWwzTHBYRDBqMFVYMC1jR2ZLbm5HWkU1bm5pYUkwdnlHWFpDa21tcVU1d19PTThxX0VLWUFHYXVxaU56WFI3NTFjRGxtZ3JiLXhRVl9RVVA5QQ?oc=5","date":"2026-02-24","type":"pipeline","source":"The Malaysian Reserve","summary":"Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight - The Malaysian Reserve","headline":"Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerg","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxPNGdPT3lScU1EUEpPRy00eDFfbnFtakJUZ2lFck5tWkdPX0lRcHR6SFlDSzVOQ0NualJVUWlEcUd3aTN3Q2xTaGFMcHFiZUJvSE8tS2tYOG14Z0xsMXRGeFVUYUx2MGxpaDhaWWVtS1R5YmdKT21qYWhjX0w4Tk4wNkRDTEJlbmpDRWNueExiMjg0UlFSOVhDZEU4cWF3UUp4SEU0UXZvWWpxaVZwQnFVTTVOLUZ1UTRQSFF3bF9PQU95NGdvV2U1WC02NUNfd2pZcGlKcEdIRHVoZTl4Vk1WY1pOZGJfWGdfeUlZQ20tQzZVTEl4NnF6UUcxdFVVZUZGUGRENklWOG4ybTFieXFGbDJJc0NFV1VYZlJuN1ZET2dwWUlDdzNsSXpBS1Y1WWll?oc=5","date":"2026-01-15","type":"pipeline","source":"PR Newswire","summary":"Hemophagocytic Lymphohistiocytosis Market Poised for Phenomenal Expansion in the US at a CAGR of 24.5% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Hemophagocytic Lymphohistiocytosis Market Poised for Phenomenal Expansion in the US at a CAGR of 24.5% During the Foreca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPV1l4ZHZYUzI0NHE5RVhSLWxhYlBvNTlFaFc5ZDZyakpNQWNPTHliZFBYdWNNWGp0Yk4wXzkxcW5NTXRfT0IxNVY2NUJDaXo5dW9QbnhUTm9hb2lfMnNLNXpOOEFjRGNrR3JSczNjSEtYRDhQX1JTSHc1dkYxTDZFWllFckZOOEZiT1A3LXQ5eUNjdmc3Q3dxcWo4WjZCdw?oc=5","date":"2025-11-25","type":"pipeline","source":"BioWorld News","summary":"Phrontline raises $60M in pre-A+ round for bispecific ADCs - BioWorld News","headline":"Phrontline raises $60M in pre-A+ round for bispecific ADCs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNenp4MDZKS2FTTmpqcFJYTHJDTWxkTEo0cGRKWno1SVBjZHluTkgtSmZjX1pVNzZsVXp3QWVmQ0lZdlRUa1pMMHV5cXJnRWtYVkhYQmZHVTY0UEZGSThwOUMzaEVKXzR6c0Nobm9PdkxLYU9pRU94XzdaUmZESkQzOWVPNl80U1liMG1XamY4dUQ2UFh3Q1dGcElXeW9NM2FjeldjWW1HZUE?oc=5","date":"2025-10-21","type":"deal","source":"BioWorld News","summary":"Post spinoff, Samsung Bioepis inks first ADC deal with Phrontline - BioWorld News","headline":"Post spinoff, Samsung Bioepis inks first ADC deal with Phrontline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE16eElydlRVSzI3NXRQX3ZfODdSMlhacG1XUG5fS1FrUmd0ZTB5VzZEMkJNU3JPZjRIelZZc2FFY1BpSGh1WnczbnhmZWxmNDlNVEx3?oc=5","date":"2025-01-06","type":"pipeline","source":"FirstWord Pharma","summary":"I-Mab shuffles pipeline, pauses CD73 programme post-Sanofi pact - FirstWord Pharma","headline":"I-Mab shuffles pipeline, pauses CD73 programme post-Sanofi pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPVWhxSmhZc0V3TExZLTVTbkxFTGY3aU5lSWgwcUYtLWNiRllNenhmeUw5el90enBmaW43amFJQTVWRnlJUGV6ejUyeE96THJLOHM1TEM5UW8xSTVLQkl2V3c3djZkbThLYkttT0N4Q1RZdkxhMTNhSFhjOGttVzF4aWFwZ3Z5a0dVOHVaS1hPRUFsOGVzeVJaQkZRYWZ3b0h2ZG50RnNleWxUdw?oc=5","date":"2025-01-03","type":"deal","source":"fiercepharma.com","summary":"Fierce Pharma Asia—Roche, Innovent's ADC deal; Lessons from AZ's China probes; Viatris' warning letter - fiercepharma.com","headline":"Fierce Pharma Asia—Roche, Innovent's ADC deal; Lessons from AZ's China probes; Viatris' warning letter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOeUNTTlZpR1JRUWw4NlV1Z2xmemNmV2l1ZXRGV0UyRVRYMnQwQ01PUzF6VjY0ZVNGbGhHUDg5V25YMnIyWWNPLXE1TWdBTDVWNlFFU0hWVXk1eGgxbko4SkJmd1Y4TEpPUUVRemRKWmdVcUNPcWsxWHdIMmhKazRvT2JvZWN6a1lIaXR6QXB0SVBtNXBIOEZrSlBB?oc=5","date":"2024-11-20","type":"pipeline","source":"Moomoo","summary":"Top 5 Health Technology Stocks in Singapore - Moomoo","headline":"Top 5 Health Technology Stocks in Singapore","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNX1NQV1JQeWRhNFBwZnZ4UGxEWi1GMXJ4NDNwVlpoZ2xYb1JSUVFtb21OVU9PSFdxMEd2UUNsYTJaUUVVQnE2UkNqcV9ucmFFa1J0eXl4OElpN0wxMmZNaXJIenE2RnlVUDlhRjktMGFFUzQwbmxkVkJDQmw0MUw4QWNWOGlkMDA?oc=5","date":"2024-11-15","type":"earnings","source":"BioSpace","summary":"I-Mab Reports Third Quarter 2024 Results - BioSpace","headline":"I-Mab Reports Third Quarter 2024 Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPeXRiZXpKQ295c3N6M3c3RG9mVWI3U2JOZ0FtQ28zQVBKZVRTRnRhaGxBMkQtZXNSRmhsNGV2Ty1OQXJnX3VMSjlxNkh1X0xOQkdNSS1WTWRFTm82eS1TQjVvUnAwQTlFQ2RmYlM2bm92bHMta3NNV2gxSmV6TkFKOVpYZUw5SU1VajUwZlRKc01Pa1ZCQXo4M05JOVc2LTlKWG5yTEZMbGxwZHVlRTFCcFNQQzMxNGY4T2dzc0Z3RXFWMHhQTTJ2S0thLWI3WWs?oc=5","date":"2024-08-28","type":"pipeline","source":"PR Newswire","summary":"I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates - PR Newswire","headline":"I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxORjN0WVR2SU9KcnRvbW43dFJkc24wUlBNM0xYdGVJVE9KdHV4eUpMYlBqd3BGamRPYTR3bWlPMXBRRDVaMTNWTXMyajBQSTFhSE5IaUZreEpFc25FQjVEbkJzNmVBUENpMkdfcFlLaElHdkZ5MGxDaEZsVHExV1BwRDFDTzNScU4xdndjRF9JaEE2emhCLTIzcGlIUDJRcjAtTTQ2TDk3cGRXWFpYWms5OWx4SUFVa3REY3ZpekFyQkxJbXFPMFkzcVI0UQ?oc=5","date":"2024-02-07","type":"pipeline","source":"PR Newswire","summary":"I-Mab Signs Agreement to Divest its Assets and Business Operations in China - PR Newswire","headline":"I-Mab Signs Agreement to Divest its Assets and Business Operations in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOY3UzekZIcURncWF0cWZKNTlIVjhpbUwzbkhIVFNGUEdiRFhoTnZMS083eVFYaWN2bGNZWURDRE9ZWkh3cXMtS040T2pMWVphS1lSUFY0ZkpNVUtzY1JvSnc4MURwVGlxSEdUWXZiTHVOS1BFdk1WWEZyUG5JRlo4V0gwSmxGMklyOGc5OEJ0d3VTSUE4YU01WlktYTNWSWhocjV3R0l2bXd6bG1Ic3pOWU95ekRibTBLQUNta0I3MA?oc=5","date":"2020-09-24","type":"deal","source":"Life Science Leader","summary":"2020 Trends In Pharma Asset Licensing And Deal Terms: A Survey Of Key Decision-Makers - Life Science Leader","headline":"2020 Trends In Pharma Asset Licensing And Deal Terms: A Survey Of Key Decision-Makers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPejhaOVBUdDhTS1pnbHdpNU00b1U4OFZub1NsOHRhN3hKdEJabXlKVGUtYWFBVV9SZnVDSmVGQ3NoMGx5S21FTGdPY3RaZmhDMHdUNjhDZW5YWFMwc3JJWGl1OFFwYkdPZDdzcXJtOHZWVjV0YnF5RHU5ZXRsd0ZNbHpUdlFIQ0lQRnpDZGRXNlBvT3JEcVh4UWQtZDBQWXhwVFBwYW12czlaZw?oc=5","date":"2020-01-02","type":"pipeline","source":"The Business Journals","summary":"Entrepreneur: Tempe startup develops tech to create more effective drugs - The Business Journals","headline":"Entrepreneur: Tempe startup develops tech to create more effective drugs","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}